Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Essentials

Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors

Jean E. Boucher
Robin Sommers
CJON 2018, 22(5), 565-568 DOI: 10.1188/18.CJON.565-568

Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with advanced GEP-NETs. Patients treated with octreotide long-acting release may be candidates for this second-line therapy. This article discusses lutetium Lu 177 dotatate therapy administration and patient care considerations.

AT A GLANCE

  • Lutetium Lu 177 dotatate therapy has been approved as a treatment for GEP-NETs.
  • Implications for lutetium Lu 177 dotatate as a second-line therapy for patients with GEP-NETs consist of radiation safety precautions and guidelines for the use of long-acting and short-acting somatostatins.
  • Considerations for this therapy include the preadministration of antiemetics and amino acid solution, as well as monitoring for side effects and toxicity.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or